Ignite Creation Date:
2024-05-06 @ 11:49 AM
Last Modification Date:
2024-10-26 @ 12:50 PM
Study NCT ID:
NCT03606395
Status:
COMPLETED
Last Update Posted:
2019-07-09
First Post:
2018-07-10
Brief Title:
Safety Tolerability PK and Efficacy of Single Doses of NV-5138 in Healthy Volunteers and Subjects With Treatment-Resistant Depression
Sponsor:
Navitor Pharmaceuticals Inc
Organization:
Navitor Pharmaceuticals Inc
Study Overview
Official Title:
A Randomized Double-Blind Placebo-Controlled Study of the Safety Tolerability Pharmacokinetics and Preliminary Efficacy of Single Doses of NV-5138 in Healthy Volunteers and Subjects With Treatment-Resistant Depression
Status:
COMPLETED
Status Verified Date:
2019-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Randomized two-part placebo-controlled study of single ascending doses of NV-5138 in healthy volunteers and a single dose of NV-5138 in subjects with Treatment-Resistant Depression TRD
Detailed Description:
This is a randomized two-part double-blind placebo-controlled study of single ascending dosage levels of NV-5138 in healthy volunteers and a single dose of NV-5138 in subjects with TRD The study includes an up to 28-day screening period an in-house period during which NV-5138 or placebo will be administered and a 3- to 7-day follow-up period after discharge
In Part A of the study single-ascending-dose SAD portion in healthy volunteers up to approximately 48 healthy volunteers will be randomly assigned to double-blind treatment Eight 8 subjects will be randomized in each of six dosage-level cohorts 150 300 600 1000 1600 or 2400 mg NV-5138 or placebo administered as an oral solution Within each cohort six subjects will be randomized to receive NV-5138 and two subjects will be randomized to receive placebo Each subject will receive only one dose of either NV-5138 or placebo on Day 1 Within each cohort initially one subject will receive NV-5138 and one subject will receive placebo Provided no clinically significant safety issues are noted in the 24 hours after dosing the initial two subjects in the cohort the six subjects remaining in the cohort may be dosed
In Part B of the study single-dose portion in subjects with TRD up to approximately 40 subjects will be randomly assigned to double-blind treatment in one cohort The dosage level for this cohort will be determined based on the safety tolerability and pharmacokinetic data from Part A of the study However in no case will the dose in Part B of the study exceed the highest dose administered in Part A of the study Within this cohort after potential eligibility has been confirmed by a site-independent review process twenty 20 subjects will be randomized to receive NV-5138 and twenty 20 subjects will be randomized to receive placebo
In Part A of the study single-ascending-dose SAD portion in healthy volunteers up to approximately 48 healthy volunteers will be randomly assigned to double-blind treatment Eight 8 subjects will be randomized in each of six dosage-level cohorts 150 300 600 1000 1600 or 2400 mg NV-5138 or placebo administered as an oral solution Within each cohort six subjects will be randomized to receive NV-5138 and two subjects will be randomized to receive placebo Each subject will receive only one dose of either NV-5138 or placebo on Day 1 Within each cohort initially one subject will receive NV-5138 and one subject will receive placebo Provided no clinically significant safety issues are noted in the 24 hours after dosing the initial two subjects in the cohort the six subjects remaining in the cohort may be dosed
In Part B of the study single-dose portion in subjects with TRD up to approximately 40 subjects will be randomly assigned to double-blind treatment in one cohort The dosage level for this cohort will be determined based on the safety tolerability and pharmacokinetic data from Part A of the study However in no case will the dose in Part B of the study exceed the highest dose administered in Part A of the study Within this cohort after potential eligibility has been confirmed by a site-independent review process twenty 20 subjects will be randomized to receive NV-5138 and twenty 20 subjects will be randomized to receive placebo
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None